146 related articles for article (PubMed ID: 31346887)
21. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases.
Chan DL; Dixon M; Law CHL; Koujanian S; Beyfuss KA; Singh S; Myrehaug S; Hallet J
Ann Surg Oncol; 2018 Jun; 25(6):1768-1774. PubMed ID: 29560571
[TBL] [Abstract][Full Text] [Related]
22. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
[TBL] [Abstract][Full Text] [Related]
23. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
[TBL] [Abstract][Full Text] [Related]
24. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
25. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.
Morgan RE; Pommier SJ; Pommier RF
Surgery; 2018 Jan; 163(1):218-225. PubMed ID: 29103583
[TBL] [Abstract][Full Text] [Related]
26. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
27. Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study.
Brighi N; Panzuto F; Modica R; Gelsomino F; Albertelli M; Pusceddu S; Massironi S; Lamberti G; Rinzivillo M; Faggiano A; Spallanzani A; Ferone D; Prinzi N; Rossi RE; Annibale B; Colao AM; Campana D
Oncologist; 2020 Mar; 25(3):259-265. PubMed ID: 32162819
[TBL] [Abstract][Full Text] [Related]
28. Metastases of pancreatic neuroendocrine tumor to the liver as extremely rare indication for liver transplantation in children. Case report and review of the literature.
Ismail H; Broniszczak D; Markiewicz-Kijewska M; Ciopiński M; Teisseyre J; Kluge P; Dembowska-Bagińska B; Kościesza A; Socha P; Kaliciński P
Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):e33-7. PubMed ID: 26850362
[TBL] [Abstract][Full Text] [Related]
29. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
30. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
[TBL] [Abstract][Full Text] [Related]
31. Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling.
Tran CG; Scott AT; Li G; Sherman SK; Ear PH; Howe JR
Surgery; 2021 Jan; 169(1):155-161. PubMed ID: 32611516
[TBL] [Abstract][Full Text] [Related]
32. Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors.
Del Prete M; Di Sarno A; Modica R; Lassandro F; Giorgio A; Bianco A; Muto M; Gasperi M; Del Prete F; Colao A; Montesarchio V; Faggiano A;
J Endocrinol Invest; 2017 Dec; 40(12):1373-1380. PubMed ID: 28667452
[TBL] [Abstract][Full Text] [Related]
33. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.
Syguła A; Ledwon A; Hasse-Lazar K; Jurecka-Lubieniecka B; Michalik B; Paliczka-Cieślik E; Zeman M; Chmielik E; Sczasny J; Jarzab B; Handkiewicz-Junak D
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3841-3851. PubMed ID: 35503379
[TBL] [Abstract][Full Text] [Related]
34. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
35. Multiple effects of somatostatin analogs verified in three cases of metastasized neuroendocrine tumors of the gastroenteropancreatic system.
Biliotti G; Martini F; Vaggelli L; Messerini L; Colagrande S; Pupi A; Seghi P
Tumori; 2006; 92(2):170-4. PubMed ID: 16724698
[TBL] [Abstract][Full Text] [Related]
36. Self-Administration of Long-Acting Somatostatin Analogues in NET Patients-Does It Affect the Clinical Outcome?
Sowa-Staszczak A; Opalińska M; Kurzyńska A; Morawiec-Sławek K; Gilis-Januszewska A; Palen-Tytko J; Olearska H; Hubalewska-Dydejczyk A
Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946232
[No Abstract] [Full Text] [Related]
37. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
38. [Antiproliferative Effect of Somatostatin Analogs - Data Analyses and Clinical Applications in the Context of the CLARINET Study].
Bencsiková B
Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
[TBL] [Abstract][Full Text] [Related]
39. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
[TBL] [Abstract][Full Text] [Related]
40. Surgical treatment of neuroendocrine tumors in the second portion of the duodenum: a single center experience and systematic review of the literature.
Iwasaki T; Nara S; Kishi Y; Esaki M; Shimada K; Hiraoka N
Langenbecks Arch Surg; 2017 Sep; 402(6):925-933. PubMed ID: 27915372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
